Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $77.73 -5.13%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 GAAP EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $23.8 million versus the consensus estimate of $23.46 million.
GUIDANCE:
Corcept Therapeutics sees FY2017 revenue of $115-125 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
